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Minimum Clinical Recommendations for diagnosis, treatment
and follow-up of newly diagnosed follicular lymphoma
Incidence
. Follicular lymphomas present worldwide the second most
frequent subtype of nodal lymphoid malignancies.
. The incidence of this disease has rapidly increased during
recent decades and has risen from 2–3/100 000/year during
the 1950 s to more than 5–7/100 000/year recently.
Diagnosis
. Diagnosis should always be based on a surgical specimen/
excisional lymph node biopsy providing enough material
for fresh frozen and formalin-fixed samples [II, A].
To ensure adequate quality, immediate processing by an
experienced pathology institute has to be guaranteed. Fine
needle aspirations or core biopsies are inappropriate for
a proper diagnosis and should only be used in the rare
patients requiring emergency treatment.
. The histological report should give the diagnosis according
to the World Health Organisation classification.
Staging and risk assessment
. Since treatment substantially depends on the stage of the
disease, initial staging should be thorough particularly in the
small proportion of patients with early stages I and II (15–
20%). Initial work-up should include a CT-scan of the
thorax, abdomen and pelvis, and a bone marrow aspirate
and biopsy [IV, C]. A complete blood count, routine blood
chemistry including LDH and uric acid as well as screening
tests for HIV and hepatitis B and C are required.
. The staging is given according to the Ann Arbor system
with mentioning of bulky disease.
. For prognostic purposes, a Follicular Lymphoma-specific
International Prognostic Index (FLIPI) has been recently
recommended [III, B].
Treatment plan
Stage I
. In the small proportion of patients with limited stages I,
radiotherapy is the treatment of choice with a curative
potential. Radiotherapy should be performed as extended
field irradiation [II, B].
. In selected patients with large tumor burden systemic
therapy as developed for advanced stages may also be used
[IV, B].
Stage II–IV
. In the large proportion of patients with advanced stage III
and IV disease no curative therapy is yet established. Since
the natural course of the disease is characterized by spon-
taneous regressions in 15–20% of cases and varies from
case to case, chemotherapy should be initiated only upon
the occurrence of symptoms including B-symptoms, hema-
topoietic impairments, bulky disease or lymphoma pro-
gression [II, B].
. If complete remission and long progression-free survival is
to be achieved, rituximab in combination with chemother-
apy (COP, CHOP and fludarabine-containing schemes such
as FCM) should be considered [I, B]. Single agent fludara-
bine or chlorambucil remain an alternative [III, B]. In
selected cases with contraindications for chemotherapy,
antibody monotherapy alone may be discussed [II, B].
Consolidation
. Meta-analysis suggests a survival benefit with interferon-a
as maintenance therapy that has to be balanced against tox-
icity. Rituximab prolonged progression-free survival in a
randomized trial. Myeloablative radiochemotherapy fol-
lowed by autologous stem cell transplantation remains
investigational [I, B].
. Radio-immunotherapy and potentially curative allogeneic
stem cell transplantation may be discussed especially in
second and higher relapses.
Response evaluation
. Adequate radiological tests should be done after ever 2–3
cycles of therapy and after completion of chemotherapy.
Patients with incomplete or lacking response should be eval-
uated for early salvage regimens.
Follow-up
. History and physical examination every 3 months for 2
years, every 6 months for 3 additional years, and sub-
sequently once a year with special attention to transform-
ation and secondary malignancies including secondary
leukemia [V, D].
. Blood count at 3, 6, 12 and 24 months, then only as needed
for evaluation of suspicious symptoms.
. Evaluation of thyroid function in patients with irradiation to
the neck at 1, 2 and 5 years.
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. Minimal adequate radiological or ultrasound examinations
at 6, 12 and 24 months after end of treatment.
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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